From microalbuminuria to hyperhomocysteinemia  by Robinson, Killian & Dennis, Vincent W.
EDITORIAL
From microalbuminuria to hyperhomocysteinemia
In 1979, Mogensen and Vittinghus in Denmark used a
sensitive radioimmunoassay to measure urine albumin, and
reported in this journal that exercise provoked transient
albuminuria in patients with diabetes mellitus for 2 to 11
years, but not in normal subjects nor in those with diabetes
for less than one year [1]. From this observation the
concept of microalbuminuria gradually emerged, a concept
which nephrologists embraced quickly and developed thor-
oughly. Microalbuminuria predicts the development of
diabetic nephropathy and is an independent risk factor for
cardiovascular mortality in type 1 and type 2 diabetes [2].
Its relationship to other major renodestructive diseases is
less clear [3]. Microalbuminuria can be reduced by angio-
tensin converting enzyme inhibitors [4], a class of drugs that
retard the progression of diabetic kidney disease. The
general theory is that microalbuminuria represents an early
and sensitive marker of vascular abnormalities, including
those of the glomerular capillary wall.
Also in 1979, Wilcken and Gupta [5] in Australia recon-
firmed that hyperhomocysteinemia occurs in chronic renal
failure, an observation made earlier by Cohen, Patel and
Kornhauser [6]. Both groups linked this abnormality to the
accelerated atherosclerosis attributed to chronic renal fail-
ure. Nephrologists remained largely unaware or uninspired
by this concept, but eventually accepted it and are now
developing it systematically. Hyperhomocysteinemia is now
established as an independent risk factor for cardiovascular
disease with or without chronic renal failure [7]. In patients
with chronic renal failure, high homocysteine concentra-
tions can be reduced by folic acid and other B vitamins [8],
a class of agents which are now being tested to retard the
progression of atherosclerotic disease. The general theory
is that hyperhomocysteinemia causes oxidative injury to the
vascular wall [9], presumably including glomerular capillar-
ies.
In this issue of Kidney International, Hoogeveen et al [10]
bring these two threads together by establishing a firm link
between microalbuminuria and hyperhomocysteinemia in
the Hoorn Study, a population-based survey of glucose
tolerance and cardiovascular risks conducted in Hoorn, the
Netherlands between 1989 and 1992. In a cross sectional
study of a random population sample of 680 Dutch men
and women between the ages of 50 and 75 years, the risk of
microalbuminuria increased with higher homocysteine con-
centrations independent of other determinants. After ad-
justment for age, gender and other classical risk factors, the
odds ratio for microalbuminuria was 1.33 per 5 mmol/liter
increment in total homocysteine concentration.
The Hoorn Study is interesting because it brings together
two investigative themes, and provocative because it indi-
cates a possible role for homocysteine in the production of
microalbuminuria. The study was not prospective and the
question arises whether the findings represent a simple
association between two surrogates. As the authors point
out, it is conceivable that hyperhomocysteinemia and mi-
croalbuminuria may arise from a common insult. Also
tenable statistically, although unattractive biologically, is
the possibility that microalbuminuria causes hyperhomo-
cysteinemia. Regardless of the interpretation, the reason-
ably ample number of subjects, the extensiveness of the
data and the thoroughness of the analysis combine to
provide a compelling association around which much more
work still needs to be done.
The Hoorn Study addressed the involvement of angio-
tensin converting enzyme inhibitors as best it could, but did
not investigate the role of B vitamins. Recent attention has
focused on folate deficiency in the production of several
chronic diseases that range from the familiar megaloblastic
anemias to neural tube defects, neuropsychiatric distur-
bances, and more recently, vascular disorders. Low folate
levels may also promote carcinogenesis. If high homocys-
teine levels, which are commonly associated with low or
relatively low folate levels, are causally related to mi-
croalbuminuria, then diabetic nephropathy and potentially
other renal disorders’ dysfunction may need to be added to
the list of conditions to which folic acid deficiency predis-
poses. This would be a shift from the currently prevailing
paradigm that hyperhomocysteinemia may mediate some
of the complications of chronic renal failure but not its
causes. By extension, folic acid should take its place
alongside ACE inhibitors on the list of agents in need of
testing for potential usefulness in retarding the progression
of chronic renal failure as well as its complications. Such a
trial would require scientific altruism because of the lack of
commercial potential. For the moment, the Hoorn Study is
welcome as a fertile observation that raises many questions
which nephrologists may want to develop further in labo-
ratory and clinical investigations.
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